Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in japanese patients with essential hypertension: Additional results from the REZALT study

Clinical Therapeutics

Volumn 32, Issue 5, 2010, Pages 861-881

  Shimada, Kazuyuki ^a   Ogihara, Toshio ^b   Saruta, Takao ^c   Kuramoto, Kizuku ^d  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d Tokyo Metropolitan Institute of Gerontology   (Japan)

Author keywords

Ambulatory blood pressure monitoring; Azelnidipine; Combination therapy; Essential hypertension; Olmesartan medoxomil

Indexed keywords

AZELNIDIPINE; OLMESARTAN;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; AZETIDINECARBOXYLIC ACID; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; TETRAZOLES;

EID: 77954783076     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.04.020     Document Type: Article

References (40)

1. Morgan TO, Anderson AI, MacInnis RJ ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens. 2001, 14:241-247.
2. Mancia G, De Backer G, Dominizak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and ofthe European Society of Cardiology (ESC). EurHeart J. 2007, 28:1462-1536. Task Force for the Management of Arterial Hypertension of the European Society of Hypertension, The Task Force for the Management of Arterial Hypertension of the European Society of CardiologyThe Task Force for the Management of Arterial Hypertension of the European Society of Cardiology.
3. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) [published correction appears in Hypertens Res. 2009;32:318]. Hypertens Res. 2009, 32:3-107. Japanese Society of Hypertension Committee.
4. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report [published correction appears in JAMA 2003;290:197]. JAMA. 2003, 289:2560-2572. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating CommitteeTreatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee.
5. Morgan T, Anderson A A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension. Am J Hypertens. 2002, 15:544-549.
6. Pickering TG, Shimbo D, Haas D Ambulatory blood-pressure monitoring. N Engl J Med. 2006, 354:2368-2374.
7. Kario K, Pickering TG, Matsuo T, et al. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension. 2001, 38:852-857.
8. Ohkubo T, Hozawa A, Yamaguchi J, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: The Ohasama study. J Hypertens. 2002, 20:2183-2189.
9. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: A prospective study. Circulation. 2003, 107:1401-1406.
10. Eguchi K, Ishikawa J, Hoshide S, et al. Night time blood pressure variability is a strong predictor for cardiovascular events in patients with type 2 diabetes. Am J Hypertens. 2009, 22:46-51.
11. Boggia J, Li Y, Thijs L, et al. Prognostic accuracy of day versus night ambulatory blood pressure: A cohort study. Lancet. 2007, 370:1219-1229. International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes (IDACO) Investigators.
12. Nagai M, Hoshide S, Ishikawa J, et al. Ambulatory blood pressure as an independent determinant of brain atrophy and cognitive function in elderly hypertension. J Hypertens. 2008, 26:1636-1641.
13. Stumpe KO Olmesartan compared with other angiotensin II receptor antagonists: Head-to-head trials. Clin Ther. 2004, 26(Suppl A):A33-A37.
14. Brunner HR, Arakawa K Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Invest. 2006, 26:185-193.
15. Brunner HR, Stumpe KO, Januszewicz A Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest. 2003, 23:419-430.
16. Oparil S Comparative antihypertensive efficacy of olmesartan: Comparison with other angiotensin II receptor antagonists. J Hum Hypertens. 2002, 16(Suppl 2):S17-S23.
17. Wellington K, Scott LJ Azelnidipine. Drugs. 2003, 63:2613-2621. discussion.
18. Wellington K, Scott LJ Azelnidipine. Drugs. 2003, 63:2623-2624.
19. Ogihara T, Saruta T, Shimada K, Kuramoto K A randomized, doubleblind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: The REZALT study. Hypertens Res. 2009, 32:1148-1154.
20. Matsui Y, Eguchi K, O'Rourke MF, et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension. 2009, 54:716-723.
21. Palatini P, Frigo G, Bertolo O, et al. Validation of the A&D TM-2430 device for ambulatory blood pressure monitoring and evaluation of performance according to subjects' characteristics. Blood Press Monit. 1998, 3:255-260.
22. Shimada K, Imai Y, Kawasaki T, et al. Guidelines for diagnosis and treatment of cardiovascular disease (1998-1999 yearly report of the research group), usage guidelines for 24-hour blood pressure monitoring devices (ABPM) [in Japanese]. Jpn Circ J. 2000, 64(Suppl V):1207-1248.
23. Kario K, Shimada K Differential effects of amlodipine on ambulatory blood pressure in elderly hypertensive patients with different nocturnal reductions in blood pressure. Am J Hypertens. 1997, 10:261-268.
24. Eguchi K, Kario K, Hoshide Y, et al. Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive pa tients. Am J Hypertens. 2004, 17:112-117.
25. Imai Y, Abe K, Nishiyama A, et al. Evaluation of the antihypertensive effect of barnidipine, a dihydropyridine calcium entry blocker, as determined by the ambulatory blood pressure level averaged for 24 h, daytime, and nighttime. Am J Hypertens. 1997, 10:1415-1419. Barnidipine Study Group.
26. Kuramoto K, Ichikawa S, Hirai A, et al. Azelnidipine and amlodipine: A comparison of their pharmaco-kinetics and effects on ambulatory blood pressure. Hypertens Res. 2003, 26:201-208.
27. Schwocho LR, Masonson HN Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol. 2001, 41:515-527.
28. Chrysant SG, Marbury TC, Robinson TD Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens. 2003, 17:425-432.
29. Smith DH, Dubiel R, Jones M Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: A comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan [published correction appears in Am J Cardiovasc Drugs. 2005;5:209]. Am J Cardiovasc Drugs 2005, 5:41-50.
30. Miura S, Fujino M, Hanzawa H, et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem. 2006, 281:19288-19295.
31. Miura S, Fujino M, Saku K Angiotensin II receptor blocker as an inverse agonist: A current perspective. Curr Hypertens Rev. 2005, 1:115-121.
32. Sada T, Mizuno M Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker [in Japanese]. Nippon Yakurigaku Zasshi. 2004, 124:257-269.
33. Uzu T, Kimura G Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation. 1999, 100:1635-1638.
34. Eguchi K, Tomizawa H, Ishikawa J, et al. Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure. J Cardiovasc Pharmacol. 2007, 49:394-400.
35. Palatini P, Julius S Heart rate and the cardiovascular risk. J Hypertens. 1997, 15:3-17.
36. Hozawa A, Ohkubo T, Kikuya M, et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: The Ohasama study. Am J Hypertens. 2004, 17:1005-1010.
37. Eguchi K, Kario K, Shimada K Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. Hypertens Res. 2002, 25:329-333.
38. Nada T, Nomura M, Koshiba K, et al. Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity. Arzneimittelforschung. 2007, 57:698-704.
39. Fujisawa M, Yorikane R, Chiba S, Koike S Chronotropic effects of azelnidipine, a slow- and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: A comparison with amlodipine. J Cardiovasc Pharmacol. 2009, 53:325-332.
40. Cuspidi C, Meani S, Salerno M, et al. Reproducibility of nocturnal blood pressure fall in early phases of untreated essential hypertension: A prospective observational study. J Hum Hypertens. 2004, 18:503-509.